ABSTRACT: Background. Spleen tyrosine kinase (Syk) is a nonreceptor tyrosine kinase and often aberrantly expressed in human cancers. However, Syk expression pattern has not yet been investigated in nasopharyngeal carcinoma (NPC). Methods. Samples of 223 NPC tissues were immunohistochemically stained for Syk expression and survival analysis was then performed. Interaction and co-localization of Syk with Epstein-Barr virus encoded latent membrane protein 2A (LMP2A) was explored.
Nasopharyngeal carcinoma (NPC) is a nonlymphomatous, epithelial carcinoma that occurs in the epithelial lining of the nasopharynx. In regions of Southern China, Southeast Asia, and North Africa, NPC is endemic, and the incidence is high. 1, 2 Genetic alterations, Epstein-Barr virus infection, and other environmental factors are reported to be associated with NPC. 3, 4 Metastasis and locoregional recurrence are the 2 major reasons for failure of treatment. 5, 6 Currently, the TNM Classification of Malignant Tumors staging is used to evaluate the prognosis of patients with NPC; however, patients with NPC with the same clinical stage often show different clinical courses, suggesting that classification by TNM staging is insufficient for precisely predicting the prognosis of this disease. Therefore, molecular biomarkers would be helpful for clinicians to identify patients with NPC with an elevated risk of poor treatment response for improvement of prognosis prediction and facilitation of therapeutic intervention.
Spleen tyrosine kinase (Syk) is a nonreceptor tyrosine kinase that contains tandem NH2 terminal Src homology 2 domains, multiple tyrosine phosphorylation sites, and a COOH-terminal tyrosine kinase domain. 7 It has been demonstrated that Syk could bind to this ITAM motif in Epstein-Barr virus encoded latent membrane protein 2A (LMP2A) in B cells and epithelial cells. 8, 9 Moreover, Syk promoter hypermethylation leading to gene silencing has been shown and reduced Syk expression correlates with tumor metastasis and poor prognosis in breast cancer, 10 pancreatic adenocarcinoma, 11 hepatocellular carcinoma, 12 bladder carcinoma, 13 and gastric carcinoma. 14 In contrast, overexpression of Syk is associated with recurrence and poor prognosis of patients with squamous cell carcinomas of the head and neck (SCCHN). 15 In addition, overexpression of Syk has also been observed in peripheral T-cell lymphomas, 16, 17 chronic lymphocytic leukemia, 18 and B-lineage acute lymphoblastic leukemia. 19 The expression pattern of Syk and its clinical significance in NPC have not been determined to date. In this study, we aimed to investigate the expression pattern of Syk in NPC and its clinicopathological implications, and to determine its potential molecular mechanisms with the goal of a better understanding of NPC.
MATERIALS AND METHODS

Patients and clinical tissue samples
For this retrospective study, archival formalin-fixed, paraffin-embedded tissue specimens from 223 patients with primary NPC who underwent radical radiotherapy from 1992 to 2002 were obtained from the Sun Yat-Sen University Cancer Center (Guangzhou, China 
Immunohistochemistry
Immunohistochemistry (IHC) was performed as described previously. 22 Syk antibody (1:200 dilution, sc-1077, Santa Cruz Biotechnology, Santa Cruz, CA) and LMP2A antibody (1:100 dilution, Proteintech Group, Chicago, IL) 23 were used. IHC results were evaluated and scored independently by 2 pathologists without knowledge of the clinicopathological outcomes of the patients.
Semiquantitative estimation was made using a composite score obtained by adding the values of staining intensity and relative abundance of positive cells. Intensity was graded as 0 (no staining), 1 (weak staining), 2 (moderate staining), or 3 (strong staining). The abundance of positive cells was graded from 0 to 3 (0, <5% positive cells; 1, 5% to 25%; 2, 26% to 50%; and 3, >50%). For Kaplan-Meier survival analysis, a composite score greater than the median value was considered high expression, and a composite score less than or equal to the median value was considered low expression. In addition, we also validated these data by comparing the cases with the highest composite score of 6 with those with a composite score of zero.
Cell Culture and Transfection
The human NPC cell lines CNE1, CNE2, and SUNE1 were cultured in RPMI 1640 medium containing 10% fetal calf serum. All cell lines were grown in a humidified incubator at 37 C with 5% CO 2 . The LMP2A-stably transfected SUNE1 and CNE2 cells (that were kindly provided by Dr. Mu-Sen Zeng, Cancer Center, Sun Yat-Sen University, Guangzhou, China) 23 were selected with 0.5 mg/mL of puromycin (SigmaAldrich, St. Louis, MO). The pFlag-LMP2A and pFlag (that were kindly provided by Dr. Fu Chen, Karolinska Institutet, Stockholm, Sweden) were transiently transfected to CNE1 cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manual, and cells were collected at 48 hours after transfection for the next experiment.
Immunofluoresence
The LMP2A-transfected NPC cells were fixed to slides with acetone at room temperature for 10 minutes. As described previously, 24 cells were incubated with LMP2A antibody (1:50 dilution, Proteintech Group) and Syk antibody (1:50 dilution, sc-1077, Santa Cruz Biotechnology) for 2 hours at 37 C, then incubated with secondary antibodies for 1 hour at 37 C. Cells were stained with 4,6-diamidino-2-phenylindole (5 ug/mL) to visualize nuclei, and examined using a fluorescence microscope.
Fluorescence in situ hybridization
Fluorescein isothiocyanate-labeled probes were: Syk:
0 . Fluorescence in situ hybridization was performed as described previously. 25 Sections were fixed with 4% paraformaldehyde at room temperature for 10 minutes. Sections were incubated with probes against Syk or LMP2A at 50 C overnight. A Tyramide Signal Amplification System (TSA; Perkin Elmer Las, Norton, OH) was used to amplify fluorescent signals. Cells were stained with diamidino-2-phenylindole (5 ug/ mL) to visualize nuclei, and examined using a fluorescence microscope.
Western blot assays
Cells were harvested and lysed with RIPA buffer. Equal amounts of denatured protein sample were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and were then transferred electrophoretically to polyvinylidene fluoride membranes for immunoblot analysis. Antibodies used for immunoblot analysis were Syk antibody (1:500 dilution, sc-1077, Santa Cruz Biotechnology) and LMP2A (1:1000 dilution, 14B7, ITN GmbH, Neuherberg, Germany) and an anti-glyceraldehyde 3-phosphate dehydrogenase antibody (1:3000 dilution, sc-32233, Santa Cruz Biotechnology) was used as loading control. All protein bands were detected using an enhanced chemiluminescent Western blot Kit (Cell Signaling Technology, Danvers, MA).
Immunoprecipitation
Equal amounts of protein lysates were incubated with Syk antibody (sc-73086, Santa Cruz Biotechnology) or control immunoglobulin (IgG) together with anti-mouse IgG agarose beads (Sigma-Aldrich) at 4 C overnight. The precipitated protein was resuspended and analyzed by immunoblotting using anti-LMP2A (1:500 dilution, 14B7, ITN GmbH). All protein bands were detected using an enhanced chemiluminescent Western blot kit (Cell Signaling Technology).
Statistical analysis
Data were analyzed using SPSS12.0 software. A chisquare test or Pearson correlation was used to determine the association between Syk expression and clinicopathological parameters and LMP2A expression. Kaplan-Meier analysis and log-rank tests were used to assess the survival rate and to compare differences in survival curves. Cox regression analysis was performed to assess the significance of multiple predictors of survival. Differences were considered significant at p < .05.
RESULTS
High expression of spleen tyrosine kinase is found in nasopharyngeal carcinoma
To evaluate the difference in Syk expression in NPC and normal epithelial cells, 3 representative NPC tumor tissues and paired adjacent normal tissues were used for Syk IHC. Strong Syk expression was observed predominantly in the cytoplasm of NPC tumor cells in all 3 NPC samples, whereas very weak expression was observed in the normal adjacent nasopharyngeal epithelium samples (Figure 1 ).
High expression of spleen tyrosine kinase correlates with clinicopathological parameters and predicts poor survival in nasopharyngeal carcinoma (Table 1) .
Overall survival (OS) analysis was performed in these 223 NPC cases (Figure 2A ). The 5-year OS rate was 68% for patients with low Syk expression (n ¼ 170), and 53% for patients with high Syk expression (n ¼ 53), which was a significant difference (p ¼ .001; Figure 2B ). No significant difference in the OS rate was seen between patients with early-stage NPC, with or without Syk high expression (p ¼ .074; Figure 2C ). In late-stage NPC, the patients with the low levels of Syk expression (n ¼ 124) had a better prognosis than the patients with high levels of Syk expression (n ¼ 45; p ¼ .014; Figure 2D ).
Furthermore, disease-free survival (DFS) analysis was also performed ( Figure 2E ). The 5-year DFS rate was and metastasis (p < .001) were prognostic predictors of OS in patients with NPC. Multivariate Cox regression analysis indicated that Syk expression had a significant, independent predictive value for survival of patients with NPC (p ¼ .033). Age (p ¼ .008), sex (p ¼ .001), recurrence (p ¼ .013), and metastasis (p < .001) were also independent prognosis predictors for patients with NPC (Table 2) .
To avoid the uncertainty of an Syk score around the median, we also compared the 5-year OS rate of the patients with NPC with the highest Syk expression (composite score 6; n ¼ 53) with those with negative Syk expression (composite score 0; n ¼ 31). The 5-year OS rate was 80% for patients with negative Syk expression, and 53% for patients with the highest Syk expression. The patients with the negative Syk expression had a much better prognosis than the patients with the highest levels of Syk expression (p ¼ .004, Supplementary Figure 1 , online only).
Latent membrane protein 2A induces spleen tyrosine kinase expression in nasopharyngeal carcinoma
To investigate the expression relationship between Syk and LMP2A in NPC, in situ hybridization and immunofluorescent (IF) were performed to detect Syk and LMP2A expression in SUNE1-LMP2A, SUNE1-vector, CNE2-LMP2A, and CNE2-vector cells. Overexpression of LMP2A mRNA led to overexpression of Syk mRNA in both SUNE1-LMP2A and CNE2-LMP2A cells ( Figure  3A and 3B) . IF also showed overexpression of Syk protein in both SUNE1-LMP2A and CNE2-LMP2A cells, compared to the control ( Figure 4A and 4B ). In addition, IF results indicated that endogenous Syk protein co-localized with LMP2A protein in both SUNE1-LMP2A and CNE2-LMP2A cells ( Figure 4A and 4B) . Moreover, Western blot further indicated LMP2A could induce Syk expression in SUNE1 cells and CNE2 cells ( Figure 5A ). Immunoprecipitation (IP) results further showed that LMP2A bound directly to Syk protein in LMP2A-expressing NPC CNE1 cells ( Figure 5B) .
IHC was performed to detect LMP2A expression in 127 cases of NPC (38 WHO type II and 89 WHO type III; Figure 5C and 5D). High expression of LMP2A was observed in 46 cases (36%) of NPC. Among the 46 LMP2A overexpressing cases, 33% (15 of 46) also showed Syk high expression. In contrast, in the 81 LMP2A low expression cases, only 12% (10 of 81) showed Syk high expression. A significant positive correlation was observed between LMP2A and Syk high expression (p ¼ .006). Moreover, high expression of LMP2A associated with the poor prognosis of patients with NPC (p ¼ .005; Figure 5E ).
DISCUSSION
In this study, we show that high expression of Syk was significantly associated with T classification and local recurrence of NPC. Our data also indicated that patients with NPC with high expression levels of Syk had shorter survival time, shorter disease-free time, and that Syk was an independent prognosis factor in NPC. These results are consistent with the study of another head and neck cancer, SCCHN, in which, Sutima et al 15 reported that overexpression of Syk was associated with recurrence and poor prognosis of the patients.
Syk has been reported to be involved in tumor metastasis in many human cancers, either suppressing or enhancing metastasis. Reduced expression of Syk could promote cell migration in breast cancer, 10 whereas overexpression of Syk could enhance cell migration in SCCHN cells. 15 However, in our study, no significant correlation was found between Syk expression and tumor metastasis. It might be because of the low number of patients with NPC with metastasis in our study. It would have been highly interesting to compare Syk expression in paired samples of primary tumors and metastasis, but such clinical material with a sufficient number of samples has not been made available as yet (biopsies are rarely removed by surgery). Taken together, our results indicate that Syk may play a key role in local NPC recurrence, and correlates with poor prognosis of patients with NPC, suggesting that Syk could be used clinically as 1 of several biomarkers for NPC prognosis.
Syk interacts selectively in immune cells with proteins containing a phosphorylated immunoreceptor tyrosinebased activation motif (ITAM) through its distinct tandem Src homology 2 domain. 26 LMP2A, which is detected in the majority of NPC cases, contains an ITAM. 27 It has been demonstrated earlier that Syk could bind to this ITAM in LMP2A in B cells and epithelial cells. 8, 9 In our study, we confirmed the interaction and co-localization of However, LMP2A has been reported to promote the degradation of Syk in B cells by ubiquitination. 28, 29 The increased expression of Syk in LMP2A-positive NPC might be a compensation for a shorter half life of Syk when LMP2A binds and affects Syk degradation. LMP2A was reported to induce cell migration and invasion in epithelial cells. 30 Lu et al 9 further demonstrated that endogenous Syk was activated in epithelial cells in the presence of LMP2A, and that Syk was required for LMP2A-triggered cell migration in epithelial cells. Taken together, these data suggested that LMP2A expression partly contributes to Syk high expression in NPC, and that Syk and LMP2A may have collaborative roles in NPC development. The precise relationship between Syk and LMP2A and the mechanism by which LMP2A induces Syk in NPC deserve further experimental studies.
In conclusion, the results of our study suggest that high expression of Syk, which is caused in part by LMP2A expression, is associated with tumor recurrence and poor prognosis of patients with NPC. Syk alone or together with LMP2A represent new biomarkers relevant to NPC prognosis. They may also be considered in therapeutic targeting strategies.
